Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Maine .
Press releases published on June 30, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
GlobeNewswire
·
June 30, 2025
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE …
AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
GlobeNewswire
·
June 30, 2025
COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU REMBOURSEMENT DES PRETS GARANTIS PAR L’ETAT L …
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
GlobeNewswire
·
June 30, 2025
Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international …
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
GlobeNewswire
·
June 30, 2025
30 Juin 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que le dernier patient a terminé l’essai …
Press release: Availability of the Q2 2025 Aide mémoire
GlobeNewswire
·
June 30, 2025
Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi …
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
GlobeNewswire
·
June 30, 2025
Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Résultats du deuxième trimestre …
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
GlobeNewswire
·
June 30, 2025
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of …
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique
GlobeNewswire
·
June 30, 2025
Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme …
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
GlobeNewswire
·
June 30, 2025
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong …
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
GlobeNewswire
·
June 30, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological …
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
GlobeNewswire
·
June 30, 2025
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering …
SEALSQ Finalizes Strategic Investment in WeCan Group with 28.30% Equity Stake Acquisition
GlobeNewswire
·
June 30, 2025
Geneva, Switzerland, June 30, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced the …